« Back
Home /
Gemcitabine

Gemcitabine

Item no.	HY-17026-500mg
Manufacturer	MedChem Express
CASRN	95058-81-4
Amount	500 mg
Quantity options	100 mg 10 mM/1 mL 1 g 200 mg 500 mg 5 g
Category	Oncology Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.94
Citations	[1]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80.\|[2]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.\|[3]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206\|[4]Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589. ACS Biomater Sci Eng. 2025 Feb 10;11(2):1222-1231. ACS Infect Dis. 2025 Oct 30. Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):317-324. Acta Biomater. 2025 Aug 27:S1742-7061(25)00640-3. Acta Pharmacol Sin. 2024 Apr;45(4):844-856. Adv Mater. 2021 May;33(18):e2100949. Adv Mater. 2025 Jul 4:e2505231. Adv Sci (Weinh). 2023 Apr;10(12):e2206004. Adv Sci (Weinh). 2023 Nov;10(33):e2302498. Adv Sci (Weinh). 2023 Oct;10(30):e2303872. Adv Sci (Weinh). 2024 Aug 23:e2400156. Adv Sci (Weinh). 2024 Nov 28:e2407519. Adv Sci (Weinh). 2025 Jan 21:e2409173. Adv Sci (Weinh). 2025 May 20:e01042. Adv Ther. 2024 Jul 18. Aging. 2020 Aug 28;12(16):16304-16325. Am J Cancer Res. 2020 Nov 1;10(11):3896-3910. Am J Cancer Res. 2020 Apr 1;10(4):1182-1193. Anticancer Drugs. 2025 Jun 13. Arch Toxicol. 2023 Dec;97(12):3209-3226. ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct. Biochem Pharmacol. 2021 Jul:189:114085. Biochem Pharmacol. 2021 Nov:193:114813. Biochem Pharmacol. 2024 Jun:224:116234. Biochem Pharmacol. 2025 Jul 18:241:117182. Biochem Pharmacol. 2025 Jul 18:241:117183. Biochim Biophys Acta Mol Basis Dis. 2025 Apr 30:167881. Biochim Biophys Acta Mol Basis Dis. 2025 Mar 31;1871(5):167814. Bioengineering (Basel). 2025 Oct 19;12(10):1121. Biol Pharm Bull. 2022 Mar 1;45(3):309-315. Biomaterials. 2022 Oct:289:121800. Biomed Pharmacother. 2019 Sep:117:109185. Biomed Pharmacother. 2022 Apr:148:112713. Biomed Pharmacother. 2023 Oct:166:115389. Bioorg Chem. 2025 May 29:163:108636. Bioorg Chem. 2025 Sep 17:165:109010. bioRxiv. 2023 Feb 28. bioRxiv. 2023 Feb 7. bioRxiv. 2023 Sep 5. bioRxiv. 2024 Aug 6:2024.03.21.586169. bioRxiv. 2024 June 12. bioRxiv. 2025 April 17. bioRxiv. 2025 February 22. bioRxiv. 2025 Jan 27:2025.01.26.634889. bioRxiv. 2025 January 02. bioRxiv. 2025 Mar 13:2025.03.11.642569. bioRxiv. 2025 Oct 9. bioRxiv. 2025 Sep 21. bioRxiv. 2025 Sep 24. BJU Int. 2025 Nov 3. Breast Cancer Res Treat. 2023 Jul;200(2):193-201. Cancer Cell Int. 2025 Oct 15;25(1):1-14. Cancer Commun (Lond). 2025 May 29. Cancer Lett. 2022 Jun 28;536:215651. Cancer Lett. 2023 Feb 1:554:216023. Cancer Lett. 2024 Nov 28:605:217284. Cancer Lett. 2025 Apr 16:217726. Cancer Lett. 2025 May 28:618:217633. Cancer Med. 2019 Oct;8(13):5903-5915. Cell Biomater. 2025 Jul 22. Cell Commun Signal. 2025 Nov 27;23(1):513. Cell Death Dis. 2025 Jan 18;16(1):28. Cell Death Dis. 2025 Jul 15;16(1):526. Cell Death Dis. 2025 Jul 4;16(1):492. Cell Death Discov. 2021 May 1;7(1):89. Cell Mol Life Sci. 2021 Dec;78(23):7505-7518. Cell Mol Life Sci. 2024 Oct 5;81(1):417. Cell Oncol (Dordr). 2025 Jun;48(3):655-671. Cell Prolif. 2021 May;54(5):e13038. Cell Rep Med. 2023 Feb 21;4(2):100911. Cell Rep Med. 2023 Oct 17;4(10):101234. Cell Rep Med. 2025 Apr 2:102053. Cell Rep Med. 2025 Sep 19:102357. Cell Rep. 2022 Aug 16;40(7):111194. Cell Rep. 2024 Apr 23;43(4):114088. Cell Rep. 2025 Jun 27;44(7):115925. Cell Rep. 2025 Nov 25;44(11):116476. Cell Res. 2020 Jul;30(7):574-589. Cell Signal. 2025 Jun 26:111965. Chem Biol Interact. 2018 Jun 25:290:44-51. Chem Eng J. 2023 Nov 17, 147466. Chem Eng J. 2024 Sep 1. Chin Chem Lett. 2017 March. Chinese Pharmacological Bulletin. 2017, 33(6): 788-792. Clin Epigenetics. 2025 May 6;17(1):77. Clin Transl Oncol. 2022 Nov;24(11):2231-2240. Commun Biol. 2024 Dec 3;7(1):1612. Curr Issues Mol Biol. 2024 Dec 11;46(12):13951-13969. Discov Oncol. 2025 Jan 3;16(1):3. DNA Cell Biol. 2022 Feb;41(2):116-127. Elife. 2022 May 3;11:e69255. Eur J Med Res. 2025 Aug 4;30(1):704. Eur J Pharm Sci. 2025 Jan 1:204:106969. Eur J Pharmacol. 2025 Dec 5:1008:178303. Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. Exp Cell Res. 2020 Dec 1;397(1):112335. Front Oncol. 2021 Jul 13:11:704042. Gastroenterology. 2021 Nov;161(5):1601-1614.e23. Heliyon. 2024 Jun 28;10(13):e33835. Hepatology. 2019 May;69(5):1995-2012. Immun Inflamm Dis. 2023 Jun;11(6):e872. Inflamm Res. 2022 Dec;71(12):1547-1557. Int Immunopharmacol. 2023 Oct:123:110709. Int J Biol Sci. 2022 Jul 4;18(11):4301-4315. Int J Biol Sci. 2022; 18(1):43-64. Int J Clin Exp Pathol. 2017;10(3):3033-3042. Int J Hyperthermia. 2024 Feb 12;41(1):2316085. Int J Med Sci. 2022 Jan 4;19(2):286-298. Int J Nanomedicine. 2025 Jun 4:20:7169-7183. Int J Oncol. 2026 Jan;68(1):10. Invest New Drugs. 2022 Apr;40(2):274-289. Invest New Drugs. 2025 Jun;43(3):728-741. iScience. 2022 Sep 6;25(10):105081. iScience. 2025 Apr 23;28(6):112509. iScience. 2025 Nov 23. J Adv Res. 2025 Nov 5:S2090-1232(25)00874-4. J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. J Biol Chem. 2017 Jun 2;292(22):9136-9149. J Biol Chem. 2023 Aug;299(8):104984. J Biomed Inform. 2023 Jun:142:104383. J Cancer Res Clin Oncol. 2024 Jul 13;150(7):348. J Cannabis Res. 2024 May 8;6(1):22. J Clin Invest. 2024 Mar 7;134(10):e172716. J Control Release. 2023 Sep:361:161-177. J Ethnopharmacol. 2024 Jun 28:328:118075. J Ethnopharmacol. 2026 Feb 28:357:120890. J Exp Clin Cancer Res. 2021 Nov 25;40(1):373. J Exp Clin Cancer Res. 2022 Oct 5;41(1):293. J Exp Clin Cancer Res. 2023 May 4;42(1):111. J Immunother Cancer. 2024 Sep 4;12(9):e009318. J Mater Chem B. 2023 Nov 8;11(43):10355-10361. J Med Chem. 2024 Sep 12;67(17):15816-15836. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. J Nanobiotechnology. 2022 Jul 6;20(1):315. J Pancreatol. 2023 Dec 12. J Pharm Biomed Anal. 2025 Nov 15:265:117063. J Pharm Pharmacol. 2025 Jan 23:rgae149. J Transl Med. 2023 Nov 21;21(1):838. J Transl Med. 2024 Dec 25;22(1):1147. J Transl Med. 2024 Dec 3;22(1):1095. J Transl Med. 2024 Jan 13;22(1):55. MAbs. 2024 Jan-Dec;16(1):2438173. Mater Today Bio. 2025 Jul 28:34:102153. Mater Today Nano. 2024 Aug. Microbiol Spectr. 2025 Aug 12. Mol Cancer. 2023 Dec 4;22(1):195. Mol Cancer. 2024 Apr 29;23(1):86. Mol Cancer. 2024 Jan 10;23(1):12. Mol Cancer. 2024 Sep 30;23(1):215. Mol Carcinog. 2024 Apr;63(4):772-784. Mol Carcinog. 2024 Oct;63(10):1953-1966. Mol Immunol. 2019 May:109:140-148. Mol Med. 2025 Apr 4;31(1):126. Mol Pharm. 2021 Jul 5;18(7):2495-2506. Mol Ther. 2025 Sep 10:S1525-0016(25)00732-4. Molecules. 2022 Oct 13;27(20):6849. Nanoscale Horiz. 2025 Jun 23;10(7):1465-1477. Nat Commun. 2024 Oct 2;15(1):8540. Nat Commun. 2025 Jul 17;16(1):6592. Nat Med. 2024 Mar;30(3):749-761. Nat Metab. 2025 Nov 13. Nature. 2019 Oct;574(7777):264-267. Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622. Onco Targets Ther. 2020 Sep 28;13:9543-9558. Oncogene. 2023 Oct;42(42):3113-3126. Oncol Lett. 2021 Aug;22(2):626. Oncol Rep. 2022 Feb;47(2):33. Oncol Res. 2024 Nov 13;32(12):1867-1879. Oxid Med Cell Longev. 2022 Sep 29;2022:3243647. Patent. US20210260092A1. Patent. US20220362387A1. Patent. US20240344020A1 Patent. US20240344020A1. PeerJ. 2025 May 30:13:e19517. Pharmaceutics. 2025 Jul 25;17(8):967. Pharmacol Res. 2024 May 9:204:107208. Phytomedicine. 2022 Sep:104:154323. Phytomedicine. 2024 Apr 26:155656. Phytomedicine. 2024 Jun:128:155527. Phytomedicine. 2024 Sep 7:135:156022. Phytomedicine. 2025 Oct 8:148:157389. Phytother Res. 2022 Aug;36(8):3313-3324. Redox Biol. 2021 Jan;38:101807. Redox Biol. 2024 May 17:73:103200. Res Sq. 2024 Sep 05. Res Sq. 2025 Jul 30. Res Sq. 2025 Mar 26. Res Sq. 2025 Oct 29. Res Sq. 2025 Sep 7. Research (Wash D C). 2025 Jul 30:8:0809. Research Square Preprint. 2021 Aug. Research Square Preprint. 2021 Nov. Research Square Preprint. 2024 Aug 19. Research Square Preprint. 2024 Jan 8. Research Square Preprint. 2024 Nov 06. Research Square Print. October 6th, 2022. RSC Adv. 2022 Oct 3;12(43):28104-28112. RSC Pharm. 2025 Oct 9. Sci Adv. 2024 Dec 13;10(50):eadq4274. Sci Adv. 2024 Jul 5;10(27):eadl1197. Sci Rep. 2024 Nov 29;14(1):29661. Sci Rep. 2025 Sep 26;15(1):33008. Sci Transl Med. 2021 Jan 20;13(577):eaba7401. SLAS Discov. 2018 Aug;23(7):687-696. SSRN. 2025 Nov 13. Stem Cells Int. 2023 Jan 30:2023:6510571. Surgery. 2024 May;175(5):1264-1275. Technol Cancer Res Treat. 2024 Jan-Dec:23:15330338241241935. Theranostics. 2021 Mar 24;11(12):5650-5674. Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. Transl Oncol. 2020 Sep;13(9):100804. Transl Oncol. 2024 Jan:39:101803. Transl Res. 2023 May:255:66-76. Universidad de Granada. 2023 Mar 27. University of Brescia. 2023 Feb 2. University of Kansas. 2025. University of Western Australia. 2024 Jul 28. View. 2023 Nov 15. Acta Biomater. 2023 Jul 1:164:407-421. Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. Adv Sci (Weinh). 2022 May;9(15):e2105894. Biomed J. 2020 Aug;43(4):368-374. Br J Pharmacol. 2021 Jun;178(12):2496-2515. Cancer Lett. 2024 Apr 10:587:216696. Cancer Res. 2023 Sep 15;83(18):3059-3076. Cell Death Dis. 2025 Aug 6;16(1):592. Chem Biol Interact. 2024 Jan 5:387:110816. Eur J Pharmacol. 2025 Sep 15:1003:177942. FASEB J. 2025 Jul 31;39(14):e70802. Heliyon. 2022 Jun 8;8(6):e09643. Int J Biol Macromol. 2025 Dec;334(Pt 1):148793. Int J Cancer. 2024 Jul 15;155(2):324-338. Int J Nanomedicine. 2023 Jul 20:18:3989-4005. J Gastroenterol. 2025 May;60(5):641-657. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. J Pharmacol Exp Ther. 2018 Oct;367(1):20-27. JCI Insight. 2022 Nov 22;7(22):e159419. Molecules. 2023 Nov 12;28(22):7552. Onco Targets Ther. 2019 Jun 12:12:4585-4593. Oncol Lett. 2023 Sep 20;26(5):473. Oncotarget. 2017 Oct 6;8(52):90185-90196. PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. SSRN. 2024 Mar 14. Urol Oncol. 2021 Mar;39(3):194.e1-194.e7.
Smiles	NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY 188011
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	263.2
Product Description	Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 200 mg/mL (ultrasonic)\|Ethanol : 12.5 mg/mL (ultrasonic)\|H2O : 6.25 mg/mL (ultrasonic; warming)
Manufacturer - Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage
Clinical information	Launched
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.